Focal adhesion kinase inhibitor TAE226 combined with Sorafenib slows down hepatocellular carcinoma by multiple epigenetic effects

Focal adhesion kinase inhibitor TAE226 combined with Sorafenib slows down hepatocellular carcinoma by multiple epigenetic effects

Abstract Background Hepatocellular carcinoma (HCC) is one of the most common and lethal malignant tumours worldwide. Sorafenib (SOR) is one of the most effective single-drug systemic therapy against advanced HCC, but the identification of novel combination regimens for a continued improvement in ove...

Full description

Bibliographic Details
Main Authors: Ilaria Romito, Manuela Porru, Maria Rita Braghini, Luca Pompili, Nadia Panera, Annalisa Crudele, Daniela Gnani, Cristiano De Stefanis, Marco Scarsella, Silvia Pomella, Stefano Levi Mortera, Emmanuel de Billy, Adrian Libenzio Conti, Valeria Marzano, Lorenza Putignani, Manlio Vinciguerra, Clara Balsano, Anna Pastore, Rossella Rota, Marco Tartaglia, Carlo Leonetti, Anna Alisi
Format: Article
Language:English
Published: BMC 2021-11-01
Series:Journal of Experimental & Clinical Cancer Research
Subjects:
HCC
FAK
Sorafenib
Epigenetic
Therapy
Online Access:https://doi.org/10.1186/s13046-021-02154-8

Internet

https://doi.org/10.1186/s13046-021-02154-8

Similar Items